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Hematolymphoid Cell Trafficking, Microchimerism, and GVH Reactions 
After Liver, Bone Marrow, and Heart Transplantation 
A.J. Demetris, N. Murase, S. Fujisaki, J.J. Fung, A.S. Rao, and T.E. Starzl 
THE RECENT discovery of ubiquitously located small 
numbers of donor leukocytes (microchimerism) in 
human kidneys, livers, and other organs1--{) up to 29 years 
posttransplantation has raised questions about the migra 
tion of the chimeric cells and their role in the induction and 
perpetuation of graft acceptance. In the human studies, the 
most prominent of the peripheralized donor leukocytes 
appeared morphologically to be the dendritic cells delin-
eated as a special white cell lineage in 1973 by Steinman 
and Cohn7- 10 and normally associated with organ immu-
nogenicity rather than tolerogenicity.II-12 We report here 
an investigation of the cell migration in unmodified versus 
immunosuppressed Brown Norway (BN) rat recipients of 
Lewis (LEW) livers with emphasis on the kinetics, loca-
tion, and the reaction elicited by these cells in the recipient 
lymphoid organs. 
We also looked for histopathologic signs in these ani-
mals of the graft versus host (OVH) reaction that we have 
postulated to be an integral part of organ graft accep-
tance.1,5,6 To magnify the OVH effect, we developed a 
model in which the lethal OVHD potential of the liver 
passenger leukocytes could be routinely demonstrated in 
the LEW to BN strain combination. 
MATERIALS AND METHODS 
Animals and Procedures 
Male Lewis (LEW, RTll) and Brown Norway (BN, RTln) rats 
(250 to 300 g) (Harlan Sprague Dawley, Inc, Indianapolis, Ind) 
were used as donors and recipients, respectively. All procedures 
and killings were under methoxyflurane anesthesia. Orthotopic 
liver transplantation (liver replacement) was with the cuff tech-
nique of Kamada and Calne,13 without arterial reconstruction. 
Heterotopic heart transplantation was to the abdominal location 
with anastomosis of the graft aorta and pulmonary artery to the 
recipient's infrarenal aorta and inferior vena cava, respectively, 14 
Bone marrow was taken from the tibias and femurs and 
processed in RPMI 1640 supplemented with 25 mmollL HEPES 
buffer, 2 mmol/L L-glutamine, penicillin (50 U/mL) and strepto-
mycin (50 J.tg/mL) (Gibco, Grand Island, NY). 
Characterization of Cell Migration 
Without Immunosuppression, Because fatal liver rejection with 
LEW ~ BN does not occur until 23 to 37 days (n = 10, see 
footnote Table 1, and group 2, Table 2), all animals (n = 12) were 
in good condition until sacrifice on days 3, 5, 7, and 14 (n = 3 
each), A piece of tissue from the liver graft, and recipient spleen, 
thymus, heart, tongue, and cervical and mesenteric lymph nodes 
were fixed in formalin for routine histopathology and a separate 
portion frozen for immunohistochemical studies. 
With Immunosuppression, Rats were treated with 1.0 mg/kg/d FK 
506 for 14 days, and once a week thereafter except for two animals 
kept for 300 postoperative days after stopping treatment at 28 
days. Three animals each were sacrificed on day 3, 5, 7, and 14 
with further sacrifices on day 28 (n = 4), 100 (n = 2), and 300 (n 
= 3), Of the three rats maintained for 300 days, one received 
weekly FK 506 until the end (Table I, group 11) while two were 
without treatment after the fourth postoperative week (Table I, 
group 12), The tissue collections were the same as in the untreated 
rats (Table I), and in addition bone marrow was examined from 
the rats kept for 3 and 300 days, 
ReCipient and Donor Cell Proliferative Response 
In the cell migration experiments, the proliferative response in the 
spleen and other lymphoid organs was monitored with two meth-
ods. Metaphase mitotic figures were counted in a standardized 
area of tissue as previously reported,15 In addition, each animal 
was injected I hour before sacrifice with 50 mg/kg IV of 5-bromo-
2' -deoxyuridine (BrdU, Sigma Chemical Co., St. Louis, Mo) in 
preparation for double immunolabelling studies of proliferating 
celis. 
Cell Phenotyping 
The monoclonal antibody L-21-6, which reacts with the invariant 
chain of class II MHC antigens of LEW and most other rat strains 
but not BN, 16 was used to differentiate donor class II MHC 
positive cells from recipient cells in the tissues. For identification 
of donor (L-21-6+) celis, the previously described avidin-biotin 
peroxidase method for localizing the bound primary antibody15 
was used with one modification. H20 2/methanol quenching of 
endogenous peroxidase activity was delayed until after incubation 
with the primary antibody, because the antigen recognized was 
found to be H20 2/methanol sensitive (unpublished observation). 
Normal LEW and BN spleens were used in each run as positive 
and negative controls, respectively, and an irrelevant primary 
antibody was substituted on each section as an additional negative 
control. The number of donor cells in recipient tissue was semi-
quantitatively estimated by counting three separate high power 
fields (HPF; 400x magnification) in tissue sections of the organ 
examined. 
For the studies of the identification of proliferating cells in the 
lymphoid organs, donor MHC class II+ cells were identified by 
the above technique, and then the dividing cells were localized 
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Table 1. Number of L-21-6+ Cells Per High-Powered Field (HPF) In Recipient (BN) Tissues at Various Times After Liver 
Transplantation in Treated and Untreated Reclpients·,t 
Days Number 
Group Post-Tx Animals Treatment Spleen MLN 
3 3 None 17 16 
2 5 3 None 7 6 
3 7 3 None 2 3 
4 14 3 None 0 0 
5 3 3 FK 506 16 17 
6 5 3 FK 506 12 11 
7 7 3 FK 506 5 6 
8 14 3 FK 506 4 7 
9 28 4 FK 506 5 8 
10 100 2 FK 506 4 14 
11 300 1 FK 506§ <1 <1 
12 300 2 FK 50611 0 <1 
"The survival of 10 untreated liver recipients (controls) was 23, 23, 23, 25, 28, 29, 29, 30, 32 and 37 days. 
fThe values shown represent the mean. 
CLN Heart 
28 0 
9 0 
3 0 
0 0 
11 0 
15 0 
7 0 
7 0 
9 <1 
14 <1 
<1 <1 
0 0 
Tongue 
0 
0 
0 
0 
0 
0 
0 
<1 
<1 
>1* 
<1 
<1 
*One had histologic evidence of low-grade GVHD. 
~reated once a week up to the time of sacrilice. Donor cells were 4-5x more plentiful than in the untreated animal (Group 12) at the same time of follow-up. 
Untreated after 28 days. 
Abbreviations: MLN, mesenteric lymph node; CLN, cervical lymph node; Tx, transplantation. 
with the monoclonal antibody against the incorporated 5-bromo-
2'-deoxyuridine (BrdU; Amersham International pic; Amersham, 
UK). 
Attempts to Categorize Lineages 
Efforts with double immunolabelling to distinguish tissue macro-
phages, dendritic cells, and T and B cells were frustrated by the 
weak and often ambiguous staining obtained when directly la-
belled (FITC conjugated), commercial reagents were used as the 
second primary immunoreactants. 
Experiments Augmenting GVH 
BN rats were infused with 2.5 x 108 LEW or BN (control) bone 
marrow cells via the penile vein on day 0 and treated then and for 
13 more days with 1.0 mglkgld FK 506, followed by single drug 
doses on days 20 and 27. All immunosuppression was then 
stopped. LEW liver (group 12, Table 2) or heart transplantation 
Table 2. IV Cell Augmentation With 2.5 x 1 l~ Bone Marrow (8M) Cells In FK 506-Treated BN Rats That Were Contemporaneously or 
Subsequently Given a Heart or Liver Allograft 
Sone LEW 
Marrow Organ Days T x* After 
Group (source) FK 50at Tx FK506 Chimerism 
Untreated Whole Organ Tx 
1 None No Heart NA 
2 None No Liver NA 
FK 506: Whole Organ Plus Recipient BMTx (Syngeneic Controls) 
3 Ves (BN) Ves Heart O§ 
4 Ves (BN) Ves Heart 45" 
5 Ves (BN) Ves Liver O§ 
6 Ves (BN) Ves Liver 4511 
FK 506: Whole Organ Plus Donor (Allogeneic) BMTx 
7 Ves (LEW) No No NA 
8 Ves (LEW) Ves No NA 
9 Ves (LEW) Ves Heart O§ 
10 Ves (LEW) Ves Heart 4511 
11 Ves (LEW) Ves Liver O§ 
12 Yes (LEW) Ves Liver 45" 
Note: Numbers underlined represent animals sacrificed for immunohistochemical studies. 
"Recipients died from GVHD. 
NT 
No 
NT 
NT 
Ves 
NT 
No 
Ves 
Ves 
Ves 
Ves 
Ves 
Rejection Survival After Tx 
+++ 7,8,8,8,8,8,10,11 
+++ 23,23,23,25,28,29,29,30,32,37 
+++ 102,102, 102, 138 
+++ 17,17,23 
0 104,104,106,>154, >154,>164 
0 132, 132, 132 
NA 91,91 
NA 30,30,100,100,100 
+ 100,100, 100 
+ 96,96,101,102 
+ 54",100 
0 21*, 22*, 22*, 23*, 37* 
tl.0 mg/kg/d on day of SM injection (day 0) and for 13 days thereafter, and then on days 20 and 27. 
*The whole organ transplant times given are days that have lapsed from the beginning (day 0) of the 28 day course of FK 506. 
§Sone marrow given and FK 506 started same day as organ transplantation. 
I Organ transplantation was 18 days after the last dose of the 28 day course of FK 506 and 45 days after the SM. 
'The death at 54 days was from a technical complication (biliary cirrhosiS/cholangitis). 
Abbreviations: NA, not applicable; Tx, transplantation; NT, not tested; SM, bone marrow. 
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(group 10, Table 2) was performed 45 days later, 18 days after the 
FK 506 treatment had ended. Histopathologic evidence of 
GVHD, chimerism, and rejection and the impact of these findings 
on mortality were the experimental end points. 
In control experiments, liver or heart transplantation was 
performed on the same day as the bone marrow infusion rather 
than at a second stage (groups 9 and 11, Table 2). Other appro-
priate controls are given in Table 2. 
RESULTS 
Leukocytes in the Liver Allografts 
Untreated Rats. As previously reported, 15 cell populations 
of the liver that normally do not express class II MHC 
antigens and therefore do not stain with L-21-6 antibody 
became universally (bile duct and sinusoid cells) or partly 
(hepatocytes) positive by day 5. This state persisted until 
the grafts failed between 23 and 37 days. Such changes in 
class II expression as a manifestation of rejection are well 
known. 17-20 
In contrast, nonparenchymal dendritic-shaped cells in 
the portal triads and in the perivenular and capsular connec-
tive tissue that normally express class II MHC rapidly 
decreased and were no longer detectable by day 5. The 
increasingly severe portal inflammatory cells signifying a 
fatal rejection were always L-21-6 negative, serving as an 
additional negative internal control for L-21-6 specificity. 
Treated Rats. The changes in the control animals were 
almost completely prevented by immunosuppression. 
There was a mild mononuclear portal infiltrate on days 5 
through 7 that was not seen in specimens obtained later 
except to a similarly minor degree at day 300 in the 
clinically well animals left untreated after 28 days. Biliary 
duct cells, sinusoidal cells, and hepatocytes were L-21-6-
throughout except in two animals untreated after 28 days 
whose L-21-6+ bile ducts had focal epithelial damage 
suggestive of low grade rejection. 
The nonparenchymal L-21-6+ (donor) cells that are 
normally found in the portal, perivenular, and capsular 
tissues remained plentiful for the first 100 days, but had 
been depleted to about 10% of normal in the animal treated 
continuously for 300 days. Cells in these locations that 
were dendritic or spindle-shaped appeared from phenotyp-
ing studies at 100 and 300 days to be of mixed recipient 
(L-21-6-) and donor (L-21-6+) origin. 
Donor Chimeric Leukocytes in ReCipient Tissues 
Untreated Animals. The number of L-21-6+ (donor) cells 
in the recipient lymphoid organs was similar with or 
without immunosuppression for up to 5 days after trans-
plantation. By 7 days, the donor class II-positive cells had 
diminished in the untreated animals, and by 14 days they 
were no longer detectable (Table 1). By this time, L-21-6 
positivity was maximal in the rejecting liver. 
Treated Animals. In contrast, all of the treated rats 
maintained their chimerism until the time of sacrifice. In 
the spleen at 3 days, donor (L-21-6+) cells were concen-
trated at the periphery of periarterial lymphatic sheath 
(PALS) B-cell follicles (Fig 1). Fewer round and dendritic-
shaped donor cells were found at the interface between the 
T-cell dependent PALS and red pulp. At 14 and 30 days in 
the treated animals, donor cells were present in the inner 
PALS. At 100 days, donor cells were found in the marginal 
zone, follicles and rarely in the red pulp, and in the inner 
PALS (Fig 2). At 300 days, donor cells were less numerous 
but in the same locations as at 100 days. 
The greatest concentration of L-21-6+ (donor) cells in 
the cervical and mesenteric lymph nodes at 3 days was in 
the cortical follicles, with the appearance of lymphocytes 
and cells with dendritic processes. There were fewer such 
cells in the interfollicular cortex. The donor cells in the 
paracortex were small and blastic. With the passage of 
time, the donor cells became more diffusely distributed 
throughout the lymph node cortex and paracortex. At 100 
days and thereafter, small round L-21-6+ cells resembling 
B lymphocytes were found in primary cortical follicles. 
Cells that looked like macrophages and dendritic cells 
were found in the paracortex. The number ofL-21-6+ cells 
at 300 days was much less than at 100 days. 
In the thymus, the evolution was much the same as in 
the other lymphoid organs with the appearance in 3 to 5 
days ofL-21-6+ cells in the medullary parenchyma as well 
as round cells in medullary septal B cell follicles (Fig 3). 
Rare round or dendritic shaped cells could be seen in the 
shrunken medulla at 28 days, often at the corticomedullary 
junction, and rare donor cells still could be found in the 
periadventitia of the medullary vessels out to 100 days. By 
this time, the medulla was severely atrophic or absent, and 
at 300 days a norn1al thymic medullary architecture could 
no longer be recognized. 
The bone marrow was examined in several animals at 
day 3, and in two of the three survivors at 300 days (one on 
and the other off weekly FK 506 treatment). Strongly and 
weakly positive L-21-6 round cells were present at 3 days 
and numbered about 1/5 HPF. Small round weakly 
L-21-6+ donor cells were found in the marrow of both 
long-term survivors. The donor cells averaged < 1130 HPF, 
with more in the animal off immunosuppression for 9 
months, than in the chronically treated rat. 
Beginning at 2 to 4 weeks, smaller numbers of donor 
class II-positive cells appeared in the tongue (or skin) and 
heart (Table 1). In both locations, these cells most com-
monly had spindle and dendritic shapes. In the tongue (Fig 
4), they were located between dermal collagen bundles, in 
the periadventitia of deep dermal arteries or surrounding 
small superficial dermal capillaries, or in the perineural 
space. In one rat, L-21-6+ donor cells were found at the 
dermal-epidermal junction of the skin at 100 days, when a 
low-grade GVHD was diagnosed histopathologically. In 
the three animals followed for 300 days, the rat under 
continuous therapy had approximately five times the num-
ber of extra lymphoid L-21-6+ cells as the two animals 
whose grafts had histopathologic evidence of low-grade 
rejection 270 days after stopping FK 506. 
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Lymphoid Proliferative Response to Liver Transplantation 
A vigorous splenic proliferative response in untreated 
animals was muted by FK 506 treatment (Fig 5). In the 
treated recipients, host splenocyte proliferation peaked at 
5 days, decreased toward baseline thereafter, but remained 
higher than that previously reported in normal BN rats or 
historical untreated BN-BN isograft controls. 15 
Double immunolabelling with L-21-6 and anti-BrdU 
showed that at 3 days (both treated and untreated animals), 
the L-21-6- proliferating recipient lymphoid cells formed 
clusters at the PALS periphery and in the red pulp. The red 
pulp clusters were not associated with L-21-6+ donor cells 
and were noticeably diminished in the FK 506 treated 
recipients. In contrast, the clusters at the PALS periphery 
were associated with L-21-6+ donor cells and not dimin-
ished by FK 506 therapy. BrdU nuclear labeling was also 
detected in 10% to 15% of L-21-6+ cells in treated and 
untreated animals (Fig 6). It could not be ruled out from 
microscopy that these were proliferating recipient T -cells 
surrounded by donor dendritic cell processes rather than 
being dividing donor cells. 
Augmentation of Passenger Leukocyte GVH Reaction 
Bone Marrow Alone. Long-term chimerism was not found 
after bone marrow transplantation in untreated rats (group 
7, Table 2). When a 4-week induction course of FK 506 
was used, chimerism was always present at 30 days and 
beyond without grossly detectable GVHD then or subse-
quently (group 8, Table 2). The density, but not the quality 
(data not shown) of this chimerism was similar to that 
following liver transplantation under comparable treat-
ment conditions (compare with group 9, Table 1). 
Bone Marrow Plus Simultaneous Liver Transplantation 
Overt GVHD was not caused in two long-surviving ani-
mals submitted to contemporaneous LEW bone marrow 
and liver transplantation under FK 506 (group 11, Table 2), 
or in BN recipients of syngeneic bone marrow and LEW 
liver grafts treated with the same immunosuppression 
(groups 5 and 6, Table 2). 
Bone Marrow Plus Staged Liver Transplantation. In 
contrast, when liver transplantation was performed 45 
days after LEW donor bone marrow infusion (18 days after 
completion of the FK 506 course), all 5 animals died of 
severe GVHD 21 to 37 days later (group 12, Table 2). 
Bone Marrow Plus Heart Transplantation. When the 
LEW heart, which was rejected by unmodified BN recip-
ient in 11 days (group 1, Table 2), was transplanted as the 
test organ following bone marrow engraftment, cardiac 
survival greater than 100 days was achieved with no 
clinically detectable GVHD whether the transplantation 
was simultaneous with the bone marrow (group 9, Table 2) 
or 45 days later-18 days after completion of the FK 506 
course (group 10, Table 2). In control animals who re-
ceived syngeneic bone marrow under FK 506 for 4 weeks, 
LEW cardiac grafts given 45 days later, experienced a 
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slightly prolonged survival (17 to 23 days), but were 
ultimately rejected (group 4, Table 2). 
Histopathologic Studies. The long-surviving LEW liver 
grafts supplemented with simultaneous LEW bone mar-
row had no evidence of rejection. However, two of three 
of the LEW heart grafts transplanted simultaneously with 
LEW bone marrow had evidence of chronic rejection with 
obliterative arteriopathy, upregulation of class II MHC on 
the arterial endothelium, and a low-grade pericardial and 
interstitial mononuclear infiltrate. Much less severe 
changes were found in the recipients in whom the heart 
was transplanted at a second stage. Immunohistochemical 
studies of extrahepatic tissues of both the liver and heart 
recipients revealed typically distributed chimeric cells. 
DISCUSSION 
The early events of cell migration after allotransplantation 
have received scant attention.21-24 The results described 
herein suggested by morphologic criteria that multiple 
leukocyte lineages are involved in addition to dendritic 
cells as we proposed earlier. l -6 However, double immu-
nolabelling did not allow precise identification of the 
lineages. Despite this limitation, an overview of the leuko-
cyte traffic was obtained. During the first 3 to 5 postoper-
ative days, donor cells homed to the lymph nodes, spleen, 
and thymus. The migratory pattern was not at first obvi-
ously affected by immunosuppression. Without treatment, 
the donor cells disappeared within a further few days, 
whereas the expected outcome with a short course of FK 
506 was permanent low-level chimerism and liver graft 
survival. 
After 2 weeks in the immunosuppressed animals, in-
creasingly dispersed donor cells could be the product of 
pluripotent stem cells like those recently cultured by Inaba 
et al from mouse blood and bone marrow, 25 or alterna-
tively, a population of more mature migratory leukocytes 
that had not reached terminal differentiation. The arrival of 
donor cells in the skin and heart after 2 to 4 weeks is not 
unique, since this occurs after bone marrow transplanta-
tion,26 which liver transplantation resembles,3 and also 
after allogeneic fetal liver transplantation. 27 
One action of drugs of the cyclosporine class includes, 
but is not limited to, selective inhibition of MHC-restricted 
alloantigen presentation. 28.29 Because FK 506 appeared in 
our experiments to deter the development oflymphoid cell 
proliferation spatially unassociated with donor class II 
MHC positive cells, it was suspected to have a similar 
action. However, such characterization of the immuno-
suppressive effects of drugs in terms of their site of 
disruption of the alloactivated T cell response cannot 
explain the donor specific nonreactivity and permanent 
acceptance of organ grafts that have been reported in 
animals after a short treatment course of every genuinely 
potent immunosuppressant during the last 30 years. We 
have postulated that the development of this nonrespon-
siveness requires bidirectional alloactivation of GVH as 
Fig 1. Recipient spleen 3 days after liver transplantation in rat treated with FK 506. MHC class 11+ donor cells are lodged primarily in the 
periphery of periarterial lymphatic sheath (P) and B-cell follicles (F) (L-21-6 IPEX [red color) with hematoxylin counterstain; original 
magnification 40 x }. The inset (original magnification 400 x ) shows the staining detail of the donor cells lodged at the periphery of the 
follicles (small arrow) . 
Fig 2. By 100 days posttransplant, donor MHC class II positive cells were less numerous in the spleen, but stm easily detectable (L-21-6 
IPEX [red color) with hematoxylin counterstain; original magnification 165 x }. A dendritic-shaped cell is seen in the PALS (large arrow) and 
a round cell in the follicle (small arrow) . The inset (original magnification 330x) shows in greater detail the dentritic-shaped cell. 
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Fig 3. Donor MHC class 11+ cells also migrated to the recipient thymus as early as 3 days after transplantation, but were few in number 
(L-21-6 IPEX) [red color) with hematoxylin counterstain; original magnification 40 x ). Note the 8 to 10 donor cells present in the small 8-cell 
follicle (large arrow) and an isolated, similarly staining cell in the thymic medulla (small arrow). The inset shows the latter cell in greater 
detail (original magnification 100x ). 
Fig 4. Donor MHC class II + cells began to appear in the tongue as early as 30 days posttransplant, and were easily detectable at 100 
days (L-21-6 IPEX [red color] with hematoxylin counterstain; original magnification 100 x ). 
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Fig. 5 Metaphase mitotic figure 
counVmm2 in the recipient spleen 
after liver transplantation in FK 
506-treated recipients (open cir-
cles) and untreated controls 
(closed circles). Note that FK 506 
diminished but did not abolish 
the splenocyte proliferation. 
Fig 6. Recipient spleen 3 days after liver transplantation in a rat treated with FK 506. The tissue section was double labelled with L-21·6 
(red) and proliferating cells (BrdU; blue nuclei). The left panel (original magnification 40 x ) shows MHC class 11+ donor cells in the B-cell 
follicles and PALS (bold arrow). The PALS are shown at higher magnification in the right panel (original magnification 1000x ). The cells 
with a blue nucleus and red cytoplasm (arrows) are thought to represent proliferating donor cells. 
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well host versus graft (HVG) varieties6 whereby a portion 
of the donor immune system in a state of initially high- and 
then low-grade stimulation is incorporated into the existing 
and similarly activated host network.30 Incompleteness of 
this assimilation is diagnosed by evidence of rejection. 
How potentially powerful and reproducible the converse 
(GVH) reaction can be was unmasked by the staged 
experiments of liver transplantation plus donor strain bone 
marrow. These two procedures done simultaneously under 
immunosuppression did not cause GVHD. However, 
when chimerism was produced with preliminary bone 
marrow transplantation under FK 506, subsequent liver 
transplantation from the donor strain following a drug-free 
interval of 18 days invariably caused lethal GVHD, resem-
bling the outcome of a parent-to-offspring F 1 hybrid exper-
iment.31 Under these circumstances, the liver including its 
virgin migratory cells was seen as self by the altered host 
immune system, but not having gone through the process 
of modification, the hepatic passenger leukocytes recipro-
cated by rejecting the recipient. 
In contrast, heterotopic hearts transplanted under the 
same circumstances of prior bone marrow preparation 
were accepted after the second stage operation without 
causing GVHD. Presumably, this reflected the smaller 
load of heart passenger leukocytes. However, a contribut-
ing factor that cannot be arbitrarily dismissed is that the 
hearts were functionless auxiliary grafts whereas the livers 
not only replaced a significant part of the recipient immune 
apparatus but filled the void of parenchymal function left 
by host hepatectomy. 
Further speCUlation about the way in which the micro-
chimerism accompanying organ transplantation affects 
global recipient immunologic reactivity awaits delineation 
of the participating cells. This information in the mouse 
liver transplantation model is reported elsewhere.32 
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